If you have spent years being told that broken sleep and hot flashes are just something to endure, you already know the conversation worth having is more nuanced than "yes or no" to hormones. Often, the more useful question is *how* estradiol is delivered — because the route can change the entire discussion.
This article is educational and is not medical advice. Whether any hormone therapy is appropriate, and in what form, is a decision for you and an independent licensed provider based on your full history.
Why delivery method is its own conversation
Estradiol is the same molecule whether it reaches your bloodstream through skin or through the digestive tract. What differs is the *path* it takes — and that path matters more than many people expect.
When estradiol is swallowed, it is absorbed through the gut and passes through the liver before reaching the rest of the body. This is called "first-pass" hepatic metabolism. The liver responds to that estrogen load by changing how it produces certain proteins, including clotting factors [1][2]. When estradiol is absorbed through the skin — a patch, gel, or spray — it largely bypasses that first liver pass and enters circulation more directly [1][3].
That single difference is why a provider may spend real time on "patch versus pill" rather than treating them as interchangeable.
Source: [1] Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study (and route/first-pass mechanism), [3] FDA: Estradiol Transdermal System — Prescribing Information (DailyMed/Drugs@FDA)
Oral estradiol: the long-studied route
Oral estradiol is the form most people picture, and it has decades of clinical use behind it. Because it is processed through the liver first, it has a measurable effect on liver-made proteins.
The relevant safety context here is venous thromboembolism (VTE) — blood clots in the veins. Observational research and society reviews have associated oral estrogen with a higher relative risk of VTE compared with transdermal routes, which appear to carry little to no added VTE risk in the populations studied [1][2][4]. This is one of the central reasons the route question is not cosmetic.
For someone like a 38-year-old navigating early surgical menopause, this distinction can be especially worth raising with a provider, because the conversation may span many years and personal-risk factors — weight, smoking history, migraine pattern, and any prior clotting events — all feed into the route discussion [2][4].
Source: [1] Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study (and route/first-pass mechanism), [2] The 2022 Hormone Therapy Position Statement of The North American Menopause Society, [4] Endocrine Society Clinical Practice Guideline: Treatment of Symptoms of the Menopause
Transdermal estradiol (patch, gel, spray)
Transdermal delivery puts estradiol through the skin and into the bloodstream while largely skipping the first liver pass [1][3]. Because of this, major menopause and endocrine guidance frequently notes that transdermal routes are often preferred when VTE risk, certain migraine patterns, or other liver-pathway concerns are part of the picture [2][4].
A patch delivers continuously over a set wear period; gels and sprays are applied to the skin and absorbed over the day. The practical trade-offs — skin irritation, transfer to others with gels, adherence, and steadiness of levels — are exactly the kind of detail a provider weighs with you, not something to self-select [3][4].
Topical/vaginal estradiol: a targeted, local route
"Cream" can mean two very different things, and the distinction matters.
Low-dose vaginal estradiol (cream, ring, or tablet) is designed to act *locally* on genitourinary tissue — vaginal dryness, irritation, and some urinary symptoms — with minimal absorption into the rest of the body [5][6]. It is generally not intended to treat whole-body symptoms like hot flashes or sleep disruption, because systemic levels stay low [5][6].
Some systemic estradiol is also formulated as a skin gel or compounded cream intended for body-wide effect; that is a different goal from local vaginal therapy. The takeaway: "a cream" is not one thing, and which tissue it is meant to reach changes the entire purpose.
A note on compounded formulations: Compounded medications are not reviewed or approved by the FDA for safety, effectiveness, or quality. Compounded products are not equivalent to or interchangeable with any FDA-approved brand-name drug. Availability varies by state.
The factors a provider actually weighs
A careful provider does not start with the product. They start with you. Common inputs include:
- Personal and family clotting history — prior VTE or known clotting conditions weigh heavily in the oral-versus-transdermal discussion [1][2][4].
- Whether you still have a uterus. If the uterus is present, estrogen is typically paired with a progestogen to protect the uterine lining; after hysterectomy, that pairing may not be needed [4][6]. For someone whose menopause began with surgery, this is a concrete reason the plan differs from a friend's.
- Migraine pattern, blood pressure, and cardiovascular history [2][4].
- Your main symptoms. Whole-body symptoms (hot flashes, sleep, mood) point toward systemic routes; isolated vaginal or urinary symptoms may be addressed locally [5][6].
- Time since menopause and age. Society guidance discusses a more favorable benefit–risk profile for many healthy people who begin hormone therapy under age 60 or within about 10 years of menopause — the "timing" framing [2][4]. This is one reason it can be reasonable to *ask*, rather than assume the window has closed.
- Preferences and adherence. A daily pill, a twice-weekly patch, and a daily gel ask different things of your routine.
The early-2000s headlines that frightened a generation were largely based on one study population using specific oral formulations, and the field has spent two decades refining how to read those findings by age, timing, and route [2][4]. A current, balanced conversation reflects that evolution rather than the original alarm.
What this means for two common situations
For someone several years into natural menopause who is still managing hot flashes and disrupted sleep, the conversation usually centers on whether a *systemic* route is appropriate and which delivery method best fits her health history and routine. Being a few years out does not automatically end the discussion — timing and individual risk are weighed together [2][4].
For someone in early or surgical menopause, the questions stretch further into the future and lean heavily on continuity: an ongoing plan, periodic reassessment, and a route choice informed by surgical history and uterine status [4][6]. The frustration of being "handed off" is real; the remedy is a relationship with a provider who treats this as a long arc, not a single appointment.
Where Velri fits
Velri is a technology and coordination company — not a medical practice. Velri can help coordinate appropriate lab work and connect you with an independent, licensed provider who reviews your history and symptoms, discusses whether hormone support is appropriate for you, and, if clinically indicated, determines the route and form. If something is prescribed, it is dispensed by an independent, licensed pharmacy. A prescription is never guaranteed; all clinical decisions rest with the independent provider.
The goal is simple: make it easier to have the current, balanced, individualized conversation you deserve — and to keep having it over time.
*This article is for education only and is not medical advice. Please consult a licensed provider about your specific situation.*
